MX2023010909A - Derivados de purina como agentes anticancerigenos. - Google Patents
Derivados de purina como agentes anticancerigenos.Info
- Publication number
- MX2023010909A MX2023010909A MX2023010909A MX2023010909A MX2023010909A MX 2023010909 A MX2023010909 A MX 2023010909A MX 2023010909 A MX2023010909 A MX 2023010909A MX 2023010909 A MX2023010909 A MX 2023010909A MX 2023010909 A MX2023010909 A MX 2023010909A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- anticancer agents
- purine derivatives
- formula
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
Los compuestos se proporcionan de acuerdo con la Fórmula (I). Fórmula (I), y sales, hidratos, solvatos, profármacos, tautómeros y estereoisómeros farmacéuticamente aceptables, así como composiciones farmacéuticas, donde el Anillo B, Anillo A, RA, Rb, Rc, Rc', R1, R2, R6, m y n son como se definen en la presente. Se contempla que los compuestos divulgados en la presente sean útiles para la prevención y el tratamiento de una variedad de afecciones.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162460P | 2021-03-17 | 2021-03-17 | |
| PCT/US2022/020700 WO2022197892A1 (en) | 2021-03-17 | 2022-03-17 | Purine derivatives as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010909A true MX2023010909A (es) | 2024-02-13 |
Family
ID=81327909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010909A MX2023010909A (es) | 2021-03-17 | 2022-03-17 | Derivados de purina como agentes anticancerigenos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240059689A1 (es) |
| EP (1) | EP4308566A1 (es) |
| JP (1) | JP2024511996A (es) |
| KR (1) | KR20240006509A (es) |
| CN (1) | CN117425656A (es) |
| AU (1) | AU2022238886A1 (es) |
| BR (1) | BR112023018799A2 (es) |
| CA (1) | CA3212292A1 (es) |
| IL (1) | IL305991A (es) |
| MX (1) | MX2023010909A (es) |
| WO (1) | WO2022197892A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023083286A1 (en) | 2021-11-12 | 2023-05-19 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| GEAP202416531A (en) * | 2021-11-12 | 2024-10-28 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| WO2024233605A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| CN117024253A (zh) * | 2023-08-14 | 2023-11-10 | 江西阿尔法高科药业有限公司 | 一种药用级麝香草酚特定杂质的制备方法 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| WO2025151705A1 (en) | 2024-01-10 | 2025-07-17 | Vrise Therapeutics, Inc. | Novel inhibitors of dna damage repair pathway |
| CN119751316A (zh) * | 2024-12-20 | 2025-04-04 | 江南大学 | 一种1-苯基三氟甲基n-（氟磺酰基）氨基甲酸酯化合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI378933B (en) * | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| JP2011236198A (ja) * | 2010-04-13 | 2011-11-24 | Daiichi Sankyo Co Ltd | モルホリノプリン誘導体 |
| US10189841B2 (en) * | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| SG11202106232TA (en) * | 2018-12-20 | 2021-07-29 | Ksq Therapeutics Inc | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
-
2022
- 2022-03-17 EP EP22717473.7A patent/EP4308566A1/en active Pending
- 2022-03-17 IL IL305991A patent/IL305991A/en unknown
- 2022-03-17 JP JP2023557285A patent/JP2024511996A/ja active Pending
- 2022-03-17 CA CA3212292A patent/CA3212292A1/en active Pending
- 2022-03-17 CN CN202280035481.2A patent/CN117425656A/zh active Pending
- 2022-03-17 BR BR112023018799A patent/BR112023018799A2/pt unknown
- 2022-03-17 KR KR1020237035424A patent/KR20240006509A/ko active Pending
- 2022-03-17 AU AU2022238886A patent/AU2022238886A1/en active Pending
- 2022-03-17 WO PCT/US2022/020700 patent/WO2022197892A1/en not_active Ceased
- 2022-03-17 MX MX2023010909A patent/MX2023010909A/es unknown
-
2023
- 2023-09-15 US US18/468,385 patent/US20240059689A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3212292A1 (en) | 2022-09-22 |
| CN117425656A (zh) | 2024-01-19 |
| KR20240006509A (ko) | 2024-01-15 |
| IL305991A (en) | 2023-11-01 |
| AU2022238886A1 (en) | 2023-09-14 |
| US20240059689A1 (en) | 2024-02-22 |
| JP2024511996A (ja) | 2024-03-18 |
| BR112023018799A2 (pt) | 2023-12-12 |
| EP4308566A1 (en) | 2024-01-24 |
| WO2022197892A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023010909A (es) | Derivados de purina como agentes anticancerigenos. | |
| MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
| MX2025000642A (es) | Compuestos macrociclicos para el tratamiento de cancer | |
| MX2020011317A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih. | |
| MX2024000299A (es) | Compuestos antivirales. | |
| MX2023014620A (es) | Nuevos profarmacos y conjugados de dimetiltriptamina. | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| PH12022550175A1 (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| MX2009012418A (es) | Derivados de quinazolin-oxima como inhibidores de hsp90. | |
| MX2024009177A (es) | Compuestos y metodos de uso | |
| TN2019000170A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| MX2023006063A (es) | Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central. | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| MX2023004033A (es) | Espiro derivados de alfa-d-galactopiranosidos. | |
| CR20240147A (es) | Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t | |
| UY27577A1 (es) | Inhibidores de la integrasa del vih | |
| MX2022007518A (es) | Derivados bencimidazol. | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2024003645A (es) | Derivados de piridinilacetamida como activadores de canales de sodio. | |
| MX2024012470A (es) | Inhibidores de cinasas dependientes de ciclina 9 (cdk9) | |
| TW200716527A (en) | Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives | |
| MX2024002674A (es) | Derivados de tiadiazolona utiles como activadores de ampk. | |
| MX2025010952A (es) | Derivados de amida para inhibir el gen nlrp3 y usos de los mismos | |
| MX2025005846A (es) | Compuestos moduladores de nmda negativos y métodos de uso de estos. | |
| MX2024003647A (es) | Derivados de piridina y su uso como activadores del canal de sodio. |